WuXi Constructs New Facility In Changzhou

Upon completion, the Changzhou facility will triple WuXi’s current capacity and employ more than 1,500 employees.

AsianScientist (May 12, 2014) – Syn-The-All (STA) Pharmaceuticals Co. Ltd., a subsidiary of the R&D services company WuXi PharmaTech Inc., has begun construction of a manufacturing site in Changzhou, about 110 miles west of Shanghai.

Hot on the heels of the announcement of WuXi’s new facility in Philapdelphia, the Changzhou site aims to meet the rapidly growing demand for WuXi’s manufacturing services, which have quadrupled their revenue in the past four years.

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Facilities constructed in the first phase will double the company’s current manufacturing capacity and be operational by the fourth quarter of 2015.

Upon completion of the entire project, the site will triple current capacity and can house more than 1,500 employees, including chemists, production staff and supporting staff.

“This project marks an important milestone in STA’s mission of building a fully integrated API development and manufacturing platform,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

——-

Source: WuXi AppTec.

Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist